Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 Brainstorm Cell Therapeutics Inc. --------------------------------------------- (Name of Issuer) Common Stock, $0.00005 par value --------------------------------------------- (Title of Class of Securities) 10501E201 --------------------------------------------- (CUSIP Number) Joseph P. Daly 497 Circle Freeway Cincinnati, Ohio 45246 (513) 943-7100 ------------------------------------------------------------------------ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 07, 2020 ------------------------------------------------------------------------ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ----------------------------------------------------------------------------------------------------------- CUSIP No. 10501E201 13D/A ----------- ----------------------------------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS Karina Daly I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) ----------------------------------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [X] ----------------------------------------------------------------------------------------------------------- 3 SEC USE ONLY ----------------------------------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) PF ----------------------------------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] ----------------------------------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States ----------------------------------------------------------------------------------------------------------- NUMBER OF SHARES 7 SOLE VOTING POWER BENEFICIALLY 110,000 ------------------------------------------------------------------------------ OWNED BY 8 SHARED VOTING POWER EACH REPORTING -0- ------------------------------------------------------------------------------ PERSON WITH 9 SOLE DISPOSITIVE POWER 110,000 ------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER -0- ------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 110,000 ----------------------------------------------------------------------------------------------------------- 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] ----------------------------------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.37% ----------------------------------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- CUSIP No. 10501E201 13D/A ----------- ----------------------------------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS EssigPR Inc. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) ----------------------------------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [X] ----------------------------------------------------------------------------------------------------------- 3 SEC USE ONLY ----------------------------------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) WC ----------------------------------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] ----------------------------------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Rincon, PR, USA ----------------------------------------------------------------------------------------------------------- NUMBER OF SHARES 7 SOLE VOTING POWER BENEFICIALLY 165,000 ------------------------------------------------------------------------------ OWNED BY 8 SHARED VOTING POWER EACH REPORTING -0- ------------------------------------------------------------------------------ PERSON WITH 9 SOLE DISPOSITIVE POWER 165,000 ------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER -0- ------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 165,000 ----------------------------------------------------------------------------------------------------------- 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] ----------------------------------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.56% ----------------------------------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) CO ----------------------------------------------------------------------------------------------------------- ITEM 1. SECURITY AND ISSUER. The class of equity security to which this statement relates is the common stock (the "Common Stock"), $0.00005 value per share ("Share"), of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the "Issuer"). The address of the principal executive offices of the Issuer is 1325 Avenue of Americas, 28th Floor, New York, NY 10019 ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Item 3 is hereby amended to read as follows: The source of funds used by the Reporting Persons are personal funds of each such person with respect to the purchases of such person, except the source of funds used for the purchases by EssigPR, Inc were from working captial. The Reporting Persons did not borrow any funds to acquire their respective shares. The following table shows the APPROXIMATE amounts of funds paid for the Shares by the Reporting Persons. Joseph P Daly $4,122,028 Karina Daly 454,304 EssigPR, Inc. 673,228 ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. Item 5 is hereby amended to read as follows: (a) The Reporting Persons hereby report beneficial ownership, in the manner hereinafter described, of 1,352,500 shares of the Issuer: (1) The foregoing percentages assume that the number of Shares of the Issuer outstanding,as reported in the Issuer's 10-Q for the quarter ended March 31, 2020 is 29,440,732 Shares (as of May 4, 2020). (2) Shares are held by EssigPR,Inc., a C corporation controlled by Joseph P. Daly (b) Joseph P. Daly has sole voting and dispositive power over his shares enumerated in paragraph (a). Karina Daly has sole voting and dispositive power over her shares enumerated in paragraph (a). EssigPR, Inc. has shared voting and dispositive power over its shares enumerated in paragraph (a). (c) Transactions for the 60 days prior to the date of this Schedule 13D : All transactions were effectuated through open-market purchases or a result of a counterparty's exercise of a derivatives contract (d) RIGHT TO RECEIVE OR POWER TO DIRECT: Not applicable. (e) DATE REPORTING PERSON CEASED TO BE 5% OWNER: 05/07/2020 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: May 08, 2020 /s/ Joseph P Daly ------------------------ Print Name: Joseph P Daly /s/ Karina Daly ------------------------ Print Name: Karina Daly EssigPR, Inc. By: /s/ Joseph P Daly ------------------------ Print Name: Joseph P Daly